Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: Development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology

Kai Temming*, Marie Lacombe, Paul van der Hoeven, Jai Prakash, Teresa Gonzalo, Eli C.F. Dijkers, László Orfi, Gyorgy Kéri, Klaas Poelstra, Grietje Molema, Robbert J. Kok

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

39 Citations (Scopus)
17 Downloads (Pure)

Fingerprint Dive into the research topics of 'Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: Development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds

Engineering & Materials Science